Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023

Vitiligo, an autoimmune disorder causing depigmented skin patches, includes two types, segmental (SV) and non-segmental (NSV). Previously, NSV was off-label treated using Calcineurine inhibitors (Tacrolimus and Pimecrolimus). In 2022, the FDA approved Ruxolitinib cream, targeting the JAK/STAT pathwa...

Full description

Saved in:
Bibliographic Details
Main Authors: Saleh F. Alqifari, Musaab Habibulla Gari, Jeff J. Guo, Shoroq Alamin, Aya K. Esmail, Abdullah K. Esmail, Heba R. Hamad, Ahmed Aljabri, Amirah M. Alatawi, Laila A. Albishi, Mohammed Olaythah Alraddadi, Helal F. Hetta
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Diseases
Subjects:
vitiligo
adverse events
FDA adverse event reporting system (FAERS)
calcineurine inhibitors
ruxolitinib
Online Access:https://www.mdpi.com/2079-9721/13/7/208
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items